Retrospective clinical-epidemiological study of patients with pemphigus and bullous pemphigoid University Hospital San Vicente Foundation
DOI:
https://doi.org/10.29176/2590843X.8Keywords:
Pemphigus, Bullous pemphigoid, Epidemiology, TherapyAbstract
In autoimmune diseases, there is loss of intercellular adhesion and alteration of the skin barrier, so that moderate to severe forms require hospital management. There are no reports on the characteristics of the patients hospitalized by these entities in the Colombian population.
The objective of this study was to describe the epidemiological and clinical characteristics of patients hospitalized for pemphigus vulgaris, pemphigus foliaceus or bullous pemphigoid treated by the Sección de Dermatología, Universidad de Antioquia at the Hospital Universitario San Vicente Fundación.
We included 99 cases, the most frequent disease being pemphigus foliaceus. Most cases were classified as moderate to severe and treatment was based on systemic steroids and azathioprine as a steroid saver. The mean hospitalization was 50.8 days for pemphigus vulgaris, 48.4 days for pemphigus foliaceus, and 39.3 days for pemphigoid blisters. The most frequent complications were infections.
These diseases require a careful approach to the complications inherent to the pathology or its treatment. They entail prolonged hospitalizations and long-term therapeutic support to avoid relapses and hospital readmissions.
Author Biographies
Diana Cristina Zuluaga, Universidad de Antioquia
Médica dermatóloga, Hospital Universitario de San Vicente Fundación; docente de cátedra, Sección de Dermatología, Universidad de Antioquia, Medellín, Colombia
Delsy Yurledy Del Río, Hospital Pablo Tobón Uribe
Médica dermatóloga, Hospital Pablo Tobón Uribe, Medellín, Colombia
Yuri Alexander Úsuga, Hospital Universitario San Vicente Fundación
Médico dermatólogo, Hospital Universitario San Vicente Fundación, sede Rionegro, Rionegro, Colombia
Daniel Camilo Aguirre-Acevedo, Universidad de Antioquia
Estadístico, Ph.D. en Epidemiología; docente, Instituto de Investigaciones Médicas, Universidad de Antioquia, Medellín, Colombia
Margarita María Velásquez, Universidad de Antioquia
Médica dermatóloga, Ph.D. en Ciencias Básicas Biomédicas; docente de Dermatología, Universidad de Antioquia; Centro de Investigaciones Dermatológicas CIDERM, Medellín, Colombia.
References
Amagay M. Pénfigo. En: Bolognia, J. Dermatología. Primera edición. Madrid, España: Elsevier; 2004. p. 449-62.
Monshi B, Marker M, Feichtinger H, Schmid G, Kriehuber E, Födinger D, et al. Pemphigus vegetans--immunopatho-logical findings in a rare variant of pemphigus vulgaris. J Dtsch Dermatol Ges. 2010;8:179-83.
Valencia OJ, Velásquez MM. Inmunopatogenia del pénfigo vulgar y el pénfigo foliáceo. Iatreia. 2011;24:272-86.
Abreu AM. Pénfigo foliáceo endémico. Situación en Co-lombia. Acta Med Colomb. 1996;21:27-34.
Diab M, Bechtel M, Coloe J, Kurtz E, Ranalli M. Treatment of refractory pemphigus erythematosus with rituximab. Int J Dermatol. 2008;47:1317-8.
Bystryn JC, Habib N. Treatment options in pemphigus. G Ital Dermatol Venereol. 2009;144:351-61.
Patricio P, Ferreira C, Gomez MM, Filipe P. Autoimmune bu-llous dermatoses: A review. Ann N Y Acad Sci. 2009;173:203-10.
Rojas- Plasencia P, Vásquez-Nuñez K. Características epide-miológicas, clínicas y supervivencia de pacientes con diag-nóstico de pénfigo atendidos en el Hospital Regional Do-cente de Trujillo. Periodo 1994-2006. Revista de la Sociedad Peruana de Dermatología. 2011; 21: 48-53.
Schmidt E, Zillikens D. The diagnosis and treatment of au-toimmune blistering skin diseases. Dtsch Arztebl Int. 2011;108:399-405.
Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris – in-cidence and mortality in the UK: Population based cohort study. BMJ. 2008;337:151-63.
Zaraa I, Kerkeni N, Ishak F, Zribi H, El Euch D, Mokni M, et al. Spectrum of autoimmune blistering dermatoses in Tu-nisia: An 11-year study and a review of the literature. Int J Dermatol. 2011;50:939-44.
Groves RW, Pemphigus: A brief review. Clin Med. 2009;9:371-5.
Markopoulos AK, Antoniades DZ, Zaraboukas T. Pemphigus vegetans of the oral cavity. Int J Dermatol. 2006;45:425-8.
Torpoco D, Ramos W, Galarza C, Gutiérrez E, González S, Ce-rrillo G. Pénfigo en un hospital general de Lima: experiencia de 10 años (1998-2007). Dermatol Perú. 2008;18:332-9.
Ljubojevic S, Lipozenčić J. Autoimmune bullous diseases as-sociations. Clin Dermatol. 2012;30:17-33.
Frew JW, Martin LK, Murrell DF. Evidence- based treatments in pemphigus vulgaris and pemphigus foliaceus. Dermatol Clin. 2011;29:599-606.
Singh S. Evidence-based treatments for pemphigus vul-garis, pemphigus foliaceus, and bullous pemphigoid: A systematic review. Indian J Dermatol Venereol Le-prol. 2011;77:456-69.
Kasperkiewicz M, Schmidt E. Current treatment of au-toimmune blistering diseases. Curr Drug Discov Technol 2009;6:270-80.
Martin LK, Agero AL, Werth V. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009(1):CD006263.
Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. A 5-year study. Int J Dermatol. 1990;29:363-7.
Schiavo AL, Puca RV, Ruocco V, Ruocco E. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies. Clin Dermatol. 2010;28:337-43.
Sebaratnam DF, Murrell DF. Objective scoring systems for disease activity in autoimmune bullous disease. Dermatol Clin. 2011;29:515-20
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
